Equities Analysts Offer Predictions for AngioDynamics Inc.’s Q2 2017 Earnings (ANGO)
AngioDynamics Inc. (NASDAQ:ANGO) – Investment analysts at KeyCorp upped their Q2 2017 earnings per share estimates for shares of AngioDynamics in a research report issued on Wednesday. KeyCorp analyst M. Mishan now expects that the brokerage will post earnings per share of $0.17 for the quarter, up from their previous estimate of $0.16. KeyCorp currently has a “Buy” rating and a $18.00 price target on the stock. KeyCorp also issued estimates for AngioDynamics’ Q3 2017 earnings at $0.13 EPS and Q4 2017 earnings at $0.18 EPS.
Separately, Zacks Investment Research upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Wednesday, September 14th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $15.20.
Shares of AngioDynamics (NASDAQ:ANGO) traded up 0.33% on Thursday, reaching $16.58. 804,550 shares of the company were exchanged. The stock’s market capitalization is $603.88 million. AngioDynamics has a 12-month low of $9.71 and a 12-month high of $17.64. The firm has a 50 day moving average price of $16.82 and a 200-day moving average price of $14.32.
AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Wednesday, October 5th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. The business had revenue of $88.10 million for the quarter. AngioDynamics had a negative net margin of 11.84% and a positive return on equity of 4.46%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business earned $0.11 earnings per share.
In related news, Director David F. Burgstahler sold 2,250,000 shares of the company’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $14.62, for a total transaction of $32,895,000.00. Following the sale, the director now directly owns 23,988 shares in the company, valued at approximately $350,704.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of the company’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $14.62, for a total transaction of $32,763,420.00. The disclosure for this sale can be found here. Corporate insiders own 1.88% of the company’s stock.
Several hedge funds have recently made changes to their positions in ANGO. Royal Bank of Canada boosted its stake in shares of AngioDynamics by 0.6% in the second quarter. Royal Bank of Canada now owns 18,000 shares of the company’s stock worth $258,000 after buying an additional 100 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of AngioDynamics by 1.5% in the second quarter. Arizona State Retirement System now owns 13,696 shares of the company’s stock worth $197,000 after buying an additional 200 shares during the last quarter. Nationwide Fund Advisors boosted its stake in shares of AngioDynamics by 0.4% in the second quarter. Nationwide Fund Advisors now owns 117,097 shares of the company’s stock worth $1,683,000 after buying an additional 430 shares during the last quarter. American International Group Inc. boosted its stake in shares of AngioDynamics by 3.9% in the second quarter. American International Group Inc. now owns 19,991 shares of the company’s stock worth $287,000 after buying an additional 754 shares during the last quarter. Finally, Thrivent Financial for Lutherans boosted its stake in shares of AngioDynamics by 7.0% in the second quarter. Thrivent Financial for Lutherans now owns 12,860 shares of the company’s stock worth $185,000 after buying an additional 840 shares during the last quarter. Institutional investors own 69.29% of the company’s stock.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.